CYPHERPUNK TECHNOLOGIES INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $13.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-12
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $9.00K, a 80.00% increase year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $5.00K.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$235.00K.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$50.00K, a 256.25% decline year-over-year.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $39.00K.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$279.00K.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$43.00K.
- CYPHERPUNK TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$162.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.00K 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $9.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $39.00K 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $21.00K 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $27.00K 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $5.00K 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | -$279.00K 10-K · filed 2026-03-16 | |||
| 2024-09-30 | -$113.00K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$123.00K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$235.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$43.00K 10-K · filed 2025-03-26 | |||
| 2023-09-30 | -$323.00K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | -$140.00K 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$50.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$162.00K 10-K · filed 2024-03-18 | |||
| 2022-09-30 | -$368.00K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$46.00K 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $32.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$33.00K 10-K · filed 2023-03-24 | |||
| 2021-09-30 | -$139.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$16.00K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$7.00K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $115.00K 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $31.00K 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$34.00K 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | -$105.00K 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$223.00K 10-K · filed 2021-03-12 | |||
| 2019-09-30 | $46.00K 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $32.00K 10-Q · filed 2020-08-13 | |||
| 2019-03-31 | -$29.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $674.00K 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $549.00K 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $262.00K 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $112.00K 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | -$618.00K 10-K · filed 2019-04-01 | |||
| 2017-09-30 | -$626.00K 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$13.00K 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | -$427.00K 10-Q/A · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |